WHERE TO FIND US NEXT?
Medicinal Chemistry Strategy Meeting at Radisson Blu, Zurich Airport, Switzerland - March 6, 2018
Who we are
ComInnex is a chemistry service organization with strong interest and background in the development of chemical technologies. The company offers flexible business models, delivers a superior added value and provides the highest customer satisfaction and return on investment to all its partners.
Our management and scientists have over 20 years experience in offering custom chemistry, chemical library development and synthesis, project management, and customer service.
Why choose us
In a world where there are an abundance of CRO companies, we are able to offer truely unique services and compound libraries through technology coupled with dedication and flexible business models.
Custom Chemistry solutions
ComInnex’s staff has served its partners for over 12 years synthesizing novel or known marker compounds or other organic molecules. The current infrastructure enables our scientists to prepare final targets from mg to 50g scale in purity up to 98%.
Our design philosophy centers on high quality lead-like libraries rather than “combinatorial-like” ones. Our screening sets are typically 100 – 300 members per library in order to sample chemical space effectively and provide medicinal chemists with excellent starting points for further optimization.
Focused & Targeted Libraries
Over the last 10 years ComInnex’s team has accumulated industry leading experience in both design and synthesis of focused libraries. Focused libraries are typically designed at ComInnex to assist our partner’s early lead follow-up efforts.
Building Blocks for DNA Encoded Libraries
Affinity selection-based screening of large DNA-encoded libraries of lead-like molecules is now a validated method to identify bioactive compounds and it represents the best avenue to interrogate protein targets with the full diversity of available chemicals.
Medicinal Chemistry Services
Hit and lead optimizations require extensive and meaningful expertise in the art. ComInnex’s medicinal chemistry leadership has developed 7 preclinical candidates that have entered the preclinical development phase. With this background we are confident that our team will take our partner’s optimization projects as far as possible and we can develop new or follow-on lead series if required.
Send us a message
Fragment Design and Synthesis
For several years ComInnex has been providing its partners with a range of exclusive and custom made fragments, meaning that our partners can access technology enabled sets of molecules synthesized either from ComInnex intermediates or commercial starting materials. Using our suite of technologies, we can also transform our partners’ intermediates to novel fragments in order to further enhance the proprietary nature of the new compounds to be synthesized.